Reuters reveals Canadian regulator considering changes to new drug pricing plan

Reuters reported exclusively that Canada’s drug pricing agency is contemplating significant changes to how it will apply new regulations aimed at lowering costs, as drugmakers unhappy with the policy delay introducing new medicines in the country and blame it for job cuts. Canada in August passed the new regulations for medicines under patent protection despite heavy lobbying from drug companies that stand to lose billions in revenue.